Separately, Zacks Investment Research upgraded Fibrocell Science from a hold rating to a buy rating and set a $0.75 target price on the stock in a research report on Tuesday, March 13th.
Shares of Fibrocell Science stock opened at $0.63 on Monday. Fibrocell Science has a 52-week low of $0.51 and a 52-week high of $4.64.
A number of institutional investors have recently added to or reduced their stakes in the business. Third Security LLC boosted its position in Fibrocell Science by 49.2% in the 4th quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after purchasing an additional 2,727,273 shares in the last quarter. Sabby Management LLC purchased a new stake in Fibrocell Science in the 4th quarter worth approximately $733,000. Armistice Capital LLC purchased a new stake in Fibrocell Science in the 4th quarter worth approximately $393,000. Anson Funds Management LP purchased a new stake in Fibrocell Science in the 4th quarter worth approximately $287,000. Finally, Pura Vida Investments LLC purchased a new stake in Fibrocell Science in the 3rd quarter worth approximately $909,000. Institutional investors and hedge funds own 48.64% of the company’s stock.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.